PAUF Pancreatic Cancer Diagnostic Kit

PAUF Pancreatic Cancer Diagnostic Kit
Product Description

Pancreatic Adenocarcinoma Up-regulated Factor- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma (PDAC). With our expertise in biosimilars and novel antibody drugs development and manufacturing, we are strongly positioned to tackle the unaddressed need of pancreatic cancer. Early detection and targeted therapy with our PBP1510 (Ulenistamab) antibody drug (currently under clinical trials) will lead to increased survival for this deadly disease. We have a Lab Developed Test ready for tech transfer and an In Vitro Diagnostic tool under development.

Read more Show less

Prestige Biopharma Limited

  • SG
  • 2018
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Categories
more categories Show less
Specifications
  • Details
    Diagnostic Kit for Pancreatic Adenocarcinoma Up-regulated Factor (PAUF) - Lab Developed Test (LDT) and In-Vitro Diagnostic (IVD)
More specifications Fewer specifications

Prestige Biopharma Limited

  • SG
  • 2018
    On CPHI since
  • 250 - 499
    Employees
Company types
Biopharmaceutical company
Contract Service
Innovation cluster
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Biopharmaceutical
View company profile

More Products from Prestige Biopharma Limited (2)

  • PBP1510 (INN:ULENISTAMAB)

    Product PBP1510 (INN:ULENISTAMAB)

    Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells an...
  • PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

    Product PBP1510 (Ulenistamab) Anti-PAUF Antibody for Pancreatic Cancer

    Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinomaup-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer.

    It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer ce...

Prestige Biopharma Limited resources (1)